Immunocore (NASDAQ: IMCR) net income
Immunocore reported a net loss of $35.5m for fiscal 2025; in fiscal 2024 it reported a net loss of $51.1m. Earnings per share were −$0.71.
Fiscal 2025 is the highest of the 4 fiscal years on record for Immunocore. It reported a loss in 4 of those 4 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$35.5m | — | −8.9% | −$0.71 |
| 2024 | −$51.1m | — | −16.5% | −$1.02 |
| 2023 | −$55.3m | — | −22.2% | −$1.13 |
| 2022 | −$52.5m | — | −30.1% | −$1.15 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Immunocore net income compared with its sector
By net income for its latest fiscal year, Immunocore ranks 228th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Immunocore, −8.9%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 226th | Arbutus Biopharma | −$33.5m | −237.9% |
| 227th | AN2 Therapeutics | −$35.2m | — |
| 228th | Immunocore | −$35.5m | −8.9% |
| 229th | Hyperfine | −$35.6m | −262.3% |
| 230th | Canton Strategic | −$35.9m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Immunocore
- How much did Immunocore earn in fiscal 2025?
- Immunocore reported a net loss of $35.5m for fiscal 2025. In fiscal 2024 it reported a net loss of $51.1m.
- What are the earnings per share of Immunocore?
- They were −$0.71 in fiscal 2025, compared with −$1.02 in fiscal 2024.
- Where does Immunocore rank in its sector by net income?
- It ranks 228th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Immunocore come from?
- From the annual report (Form 10-K) that Immunocore files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Immunocore files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022. More on Immunocore: the Immunocore page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.